Literature DB >> 29537936

Isolation and characterization of a monoclonal antibody containing an extra heavy-light chain Fab arm.

Dan Boyd1, Arpa Ebrahimi1, Sarah Ronan1, Brian Mickus1, Matthew Schenauer1, Jenny Wang1, Darren Brown1, Alexandre Ambrogelly1.   

Abstract

Isolation and characterization of monoclonal antibody (mAb) variants to understand the impact of their structure on function is a typical activity during early-stage candidate selection that contributes to derisking clinical development. In particular, efforts are devoted to characterizing oligomeric variants, owing to their potential immunogenic nature. We report here a mAb variant consisting of a canonical mAb monomer associated in a non-covalent fashion with an antigen-binding fragment (Fab) arm amputated from its Fc domain. The truncated heavy chain is encoded in the cell line genome and is the likely product of a genomic recombination during cell line generation. The addition of the Fab arm results in severe loss of potency, indicating its interaction with the Fab domain of the monomer. The presence of such a variant can easily be mitigated by an adequate purification step.

Keywords:  SEC-MALS; antibody impurities; cell line; high molecular weight species; mAb; molecular size variant; monoclonal antibody; size exclusion chromatography

Mesh:

Substances:

Year:  2018        PMID: 29537936      PMCID: PMC5916558          DOI: 10.1080/19420862.2018.1438795

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  22 in total

1.  Analytical characterization of a monoclonal antibody therapeutic reveals a three-light chain species that is efficiently removed using hydrophobic interaction chromatography.

Authors:  Rachel B Wollacott; Paul L Casaz; Trevor J Morin; H Lily Zhu; Roger S Anderson; Gregory J Babcock; John Que; William D Thomas; Sadettin S Ozturk
Journal:  MAbs       Date:  2013-08-19       Impact factor: 5.857

2.  Rapid identification of an antibody DNA construct rearrangement sequence variant by mass spectrometry.

Authors:  Rebecca A Scott; Rich Rogers; Alain Balland; Lowell J Brady
Journal:  MAbs       Date:  2014       Impact factor: 5.857

3.  A chemical and computational approach to comprehensive glycation characterization on antibodies.

Authors:  Ramsey A Saleem; Brittany R Affholter; Sihong Deng; Phil C Campbell; Kelli Matthies; Catherine M Eakin; Alison Wallace
Journal:  MAbs       Date:  2015       Impact factor: 5.857

Review 4.  In vitro and in vivo modifications of recombinant and human IgG antibodies.

Authors:  Hongcheng Liu; Gomathinayagam Ponniah; Hui-Min Zhang; Christine Nowak; Alyssa Neill; Nidia Gonzalez-Lopez; Rekha Patel; Guilong Cheng; Adriana Z Kita; Bruce Andrien
Journal:  MAbs       Date:  2014-10-30       Impact factor: 5.857

5.  Characterization of monoclonal antibody size variants containing extra light chains.

Authors:  Connie Lu; Dandan Liu; Hongbin Liu; Paul Motchnik
Journal:  MAbs       Date:  2012-12-19       Impact factor: 5.857

6.  Structural analysis of a therapeutic monoclonal antibody dimer by hydroxyl radical footprinting.

Authors:  Galahad Deperalta; Melissa Alvarez; Charity Bechtel; Ken Dong; Ross McDonald; Victor Ling
Journal:  MAbs       Date:  2012-12-17       Impact factor: 5.857

7.  Identification of a single base-pair mutation of TAA (Stop codon) → GAA (Glu) that causes light chain extension in a CHO cell derived IgG1.

Authors:  Taylor Zhang; Yungfu Huang; Scott Chamberlain; Tony Romeo; Judith Zhu-Shimoni; Daniel Hewitt; Mary Zhu; Viswanatham Katta; Brad Mauger; Yung-Hsiang Kao
Journal:  MAbs       Date:  2012-09-27       Impact factor: 5.857

8.  Structure-based prediction of asparagine and aspartate degradation sites in antibody variable regions.

Authors:  Jasmin F Sydow; Florian Lipsmeier; Vincent Larraillet; Maximiliane Hilger; Bjoern Mautz; Michael Mølhøj; Jan Kuentzer; Stefan Klostermann; Juergen Schoch; Hans R Voelger; Joerg T Regula; Patrick Cramer; Apollon Papadimitriou; Hubert Kettenberger
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

Review 9.  Immunogenicity of therapeutic proteins: influence of aggregation.

Authors:  Kirsty D Ratanji; Jeremy P Derrick; Rebecca J Dearman; Ian Kimber
Journal:  J Immunotoxicol       Date:  2013-08-06       Impact factor: 3.000

Review 10.  Posttranslational Modifications and the Immunogenicity of Biotherapeutics.

Authors:  Roy Jefferis
Journal:  J Immunol Res       Date:  2016-04-14       Impact factor: 4.818

View more
  2 in total

1.  Expression vector-derived heterogeneity in a therapeutic IgG4 monoclonal antibody.

Authors:  Douglas S Rehder; Chris J Wisniewski; Denfeng Liu; Diya Ren; Dell Farnan; Matthew R Schenauer
Journal:  MAbs       Date:  2018-11-07       Impact factor: 5.857

2.  Identification and characterization of an IgG sequence variant with an 11 kDa heavy chain C-terminal extension using a combination of mass spectrometry and high-throughput sequencing analysis.

Authors:  Claire Harris; Weichen Xu; Luigi Grassi; Chunlei Wang; Abigail Markle; Colin Hardman; Richard Stevens; Guillermo Miro-Quesada; Diane Hatton; Jihong Wang
Journal:  MAbs       Date:  2019-10-01       Impact factor: 5.857

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.